ginisortamab + trifluridine + tipiracil

This entry refers to a **combination therapy** of ginisortamab, trifluridine, and tipiracil. - **Ginisortamab** is a first-in-class monoclonal antibody targeting and neutralizing **gremlin-1**, a protein that inhibits bone morphogenetic protein (BMP) signaling and is associated with tumor progression in certain cancers, including pancreatic ductal adenocarcinoma. By inhibiting gremlin-1, ginisortamab aims to restore BMP tumor-suppressor activity, potentially making tumor cells more sensitive to chemotherapy[1][3][5][9]. - **Trifluridine** is a nucleoside analog that is incorporated into DNA, leading to DNA dysfunction and cytotoxicity in cancer cells. **Tipiracil** is a thymidine phosphorylase inhibitor that prevents the breakdown of trifluridine, increasing its bioavailability and allowing for effective oral administration[2][4]. The fixed-dose combination of trifluridine/tipiracil is marketed as Lonsurf and is approved for previously treated metastatic colorectal cancer and gastric cancer[2][4]. - There is no evidence in the search results that this specific triple combination (ginisortamab + trifluridine + tipiracil) has a unique clinical trial, product, or regulatory approval. - The combination would hypothetically offer dual mechanisms: (1) restoring tumor suppressor signaling (ginisortamab), and (2) direct cytotoxicity to rapidly dividing cancer cells (trifluridine/tipiracil).

Brand names

Lonsurf

Other names

FTD–TPItrifluridine/tipiracil